Keyword: Celsius Therapeutics
The public markets have been receptive to early-stage biotechs but will the IPO remain open? We asked our Fierce 15 winners what they thought.
Celsius is using a new set of tools it thinks will unlock some of the secrets of autoimmune diseases and cancer—notably those that do not have a specific genomic mutation, which make up about 70% of all cancers.
